Publication & Citation Trends
Publications
0 total
Antisense oligonucleotides ameliorate kidney dysfunction in podocyte specific APOL1 risk variant mice. OA
Cited by 15
Semantic Scholar
Silencing of STE20‐type kinase MST3 in mice with antisense oligonucleotide treatment ameliorates diet‐induced nonalcoholic fatty liver disease OA
Cited by 24
Semantic Scholar
Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data OA
Cited by 74
Semantic Scholar
Correcting β-thalassemia by combined therapies that restrict iron and modulate erythropoietin activity. OA
Cited by 35
Semantic Scholar
Antisense oligonucleotide treatment ameliorates IFN-γ-induced proteinuria in APOL1-transgenic mice. OA
Cited by 89
Semantic Scholar
Stk25 antisense oligonucleotide treatment reverses glucose intolerance, insulin resistance, and NAFLD in mice
Cited by 0
Semantic Scholar
Antisense oligonucleotide-mediated Dnm2 knockdown prevents and reverts myotubular myopathy in mice OA
Cited by 85
Semantic Scholar
Antisense Reduction of Mutant COMP Reduces Growth Plate Chondrocyte Pathology. OA
Cited by 21
Semantic Scholar
Research Topics
Iron Metabolism and Disorders
(6)
Hemoglobinopathies and Related Disorders
(6)
Liver Disease Diagnosis and Treatment
(4)
Metabolism, Diabetes, and Cancer
(4)
Adipose Tissue and Metabolism
(4)
Affiliations
Ionis Pharmaceuticals (United States)
Antisense Therapeutics (Australia)